Pfizer Inc. (PFE) — closed signal from September 4, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 3, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published September 4, 2025
Pfizer looks like a rebound idea: the price has been weak, but short-term signals show it may be overly beaten down, and investor interest is still there. A new trial partnership with Olema could add more potential medicines, which can attract attention from larger players. Trend readings are still negative, so waiting for the price to firm up makes sense. Over the next few months, a steady recovery is possible if study news rebuilds trust.
Primary drivers
- Short-term readings suggest shares look too beaten down for current news
- New Olema partnership could broaden the drug pipeline and spark interest
- Healthcare stocks often hold up better when markets get choppy
- Need clear signs the price is turning up before getting more aggressive
How it played out
PFE: the peak cleared the target, then faded
Lyra published PFE on 2025-09-04 at 24.17 as a short-term rebound idea. The thesis expected 14% growth toward 27.08. It pointed to shares looking too beaten down, a new Olema partnership that could broaden the pipeline, steadier healthcare behavior in choppy markets, and the need for clearer signs that the price was turning up.
Inside the window, PFE peaked at 27.21 on 2025-10-03. That was above the 27.08 target, with a recorded peak gain of 12.6%. The record did not mark a target date. By 2025-12-03, it ended at 25.57. The thesis partly played out: the rebound reached the target area, but it did not hold.
What happened during the window
On 2025-10-01, The Wall Street Journal reported that Pfizer had agreed to offer some drugs at reduced prices through a new U.S. government website. During the same window, clinicaltrials.gov listed a Pfizer Phase 3 trial record for ibuzatrelvir dated 2025-09-08.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.